<DOC>
	<DOCNO>NCT00561704</DOCNO>
	<brief_summary>Insulin resistance typically characterize type 2 diabetes ( T2DM ) prediabetic state prominent feature metabolic syndrome.Adiponectin play important part glucose metabolism , insulin resistance , deterioration renal function.we hypothesize difference serum adiponectin level obese non-obese woman type 2 diabetic nephropathy . Furthermore , two group would respond difference RAs blocker ( Losartan ) .</brief_summary>
	<brief_title>Adiponectin Obese Women With T2DN Effects RAS Blocker</brief_title>
	<detailed_description>would prospective cohort study . According BMI , woman , age &gt; 30yr , diagnose type 2 diabetic nephropathy , chronic kidney disease stage range 1 4 , divide two group . Renal function index ( include SCr , GFR , et al ) , glucose metabolism index ( fast glucose , plasma insulin et al ) , adiponectin concentration observe record . two group female accept treatment RAS blocker ( losartan , 100mg daily , 6 month ) . study , mention parameter also record 3 month interval . Meanwhile , side effect would pay attention .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<criteria>Type 2 diabetic nephropathy CKD stage 1~4 Type 1 diabetes nondiabetic renal disease An elevated plasma K level .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>obese female</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>Glucose Metabolism</keyword>
	<keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
	<keyword>Adiponectin</keyword>
</DOC>